Dual-targeted Therapy Plus Chemotherapy Doubles Survival in BRAF-Mutated Metastatic Colorectal Cancer
In a groundbreaking advancement that could redefine the prognosis for a challenging subset of metastatic colorectal cancer (mCRC) patients, the BREAKWATER phase 3 clinical trial...